Posts by Peter W. PENG

The 2026 CSCO Academic Annual Meeting was held in Jinan from September 16 to 19, bringing together oncology experts from China and around the world. On this occasion, Oncology Frontier invited Professor Yi-Long Wu of Guangdong Provincial People's Hospital to speak with Professor Everett Vokes, Chair of the Department of Medicine at the University of Chicago and former President of the American Society of Clinical Oncology (ASCO). Their discussion explored the biological characteristics of MET-amplified non-small cell lung cancer (NSCLC), the current diagnostic and treatment landscape in China and the United States, and future directions for international collaboration.

At the selected target dose of 60 mg, obrixtamig combined with standard therapy as first-line induction and maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) achieved an objective response rate of 76% and a 6-month progression-free survival rate of 85%. The safety profile was consistent with the known safety profiles of the individual agents.

The 2026 Congress of the European Society for Medical Oncology (ESMO) is fast approaching. Yizekang (lunvenlatug vedotin, BL-B01D1/iza-bren), the world's first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC), has achieved the primary endpoint in PANKU-Breast01, a randomized, controlled Phase III clinical trial in patients with HR+/HER2− advanced breast cancer whose disease progressed after endocrine therapy plus a CDK4/6 inhibitor and who had failed one to two lines of chemotherapy. The study has been selected for a Late-Breaking Abstract (LBA), one of the highest-profile presentation categories at the ESMO Congress. Oncology Frontier invited Professor Yongmei Yin of Jiangsu Province Hospital to discuss unmet clinical needs, analyze the potential clinical value of bispecific ADCs, and share her expert insights.

As the world's first approved EGFR × HER3 bispecific antibody–drug conjugate (ADC), Izecom (izalontamab brengitecan, BL-B01D1/iza-bren) features a dual-target structure designed to overcome the limitations associated with low or heterogeneous expression of a single target. It has demonstrated remarkable antitumor activity across multiple tumor types. The phase III PANKU-Breast02 study, jointly led by Professor Jiong Wu and Professor Jian Zhang of Fudan University Shanghai Cancer Center, reported positive results for both primary endpoints, progression-free survival (PFS) and overall survival (OS), in a high-profile late-breaking abstract (LBA) presentation at ASCO. In recognition of its breakthrough clinical value, the study also received the 2026 Innovative Research Award at this year's CSCO Annual Meeting. These achievements indicate that the clinical value of izalontamab brengitecan in breast cancer is attracting global attention and recognition.

The 2026 Xianghu Breast Cancer Treatment Frontiers Conference (hereinafter referred to as the “Xianghu Forum”) is currently underway. Building on previous editions, this year's meeting has been comprehensively upgraded, focusing on international advances such as antibody–drug conjugates (ADCs) and novel targeted therapies, incorporating real-world data from China and Zhejiang Province, and strengthening interdisciplinary exchange, multidisciplinary collaboration, and the development of young and mid-career physicians. These efforts aim to bring high-quality breast cancer care closer to the clinical frontline. During the meeting, Oncology Frontier interviewed Professor Xiaojia Wang of Zhejiang Cancer Hospital, Chair of the Conference, to discuss the meeting's highlights and distinctive features, the significance of the Hangzhou session of the CSCO BC Guidelines Tour in advancing standardized and consistent breast cancer care, and the emerging landscape of precision diagnosis and treatment for HR-positive advanced breast cancer. He also shared valuable insights into original research, data sharing, multidisciplinary collaboration, and the professional development of young and mid-career physicians.

The 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) will be held under the theme “Upholding Standards and Embracing Digital Intelligence and Innovation,” showcasing research achievements and clinical advances across oncology. As an important platform connecting standardized diagnosis and treatment, innovative research, and international exchange, this year's meeting features several new highlights in its scale of participation, presentation of original research, and academic session offerings.

Clinical research into precision breast cancer treatment has continued to advance in recent years. On the one hand, the applications of circulating tumor DNA (ctDNA) testing are expanding beyond pretreatment target identification and treatment selection to include dynamic monitoring throughout treatment and intervention before radiographic disease progression. On the other hand, ADC development continues to evolve, with target design moving from single-target to increasingly diverse approaches, opening up new treatment options, particularly for patients who develop resistance. At the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), Oncology Frontier invited Professor Yanxia Shi of Sun Yat-sen University Cancer Center to discuss the latest international evidence on two cutting-edge topics: ctDNA-guided intervention before radiographic progression and the mechanistic differences among ADCs. She also explored recent advances in precision breast cancer treatment and their implications for clinical practice.

Translating evidence from clinical trials into routine clinical practice involves multiple stages, including translational research, regulatory approval, reimbursement, and adaptation to clinical settings. Overcoming these challenges is a shared priority for the global oncology community.

The 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, China. At the meeting, Professor Qiang Wei of the Department of Urology at West China Hospital, Sichuan University, presented a poster based on real-world data from the US Veterans Health Administration (VHA), focusing on patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) who were older, frail, or had a high burden of comorbidities.